Sutkowska Joanna, Hupert Natalia, Gawron Katarzyna, Strawa Jakub W, Tomczyk Michał, Forlino Antonella, Galicka Anna
Department of Medical Chemistry, Medical University of Bialystok, ul. Mickiewicza 2A, 15-222 Bialystok, Poland.
Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Pharmaceutics. 2021 Jun 23;13(7):938. doi: 10.3390/pharmaceutics13070938.
Rosemary extract (RE) and lemon balm extract (LBE) attract particular attention of pharmacists due to their high therapeutic potential. Osteogenesis imperfecta (OI) type I is a heritable disease caused by mutations in type I collagen and characterized by its reduced amount. The aim of the study was to evaluate the effect of the extracts and rosmarinic acid (RA) on collagen type I level in OI skin fibroblasts. Phytochemical analysis of RE and LBE was carried out by liquid chromatography-photodiode array detection-mass spectrometry. The expression of collagen type I at transcript and protein levels was analyzed by qPCR, ELISA, SDS-urea PAGE, and Western blot. In OI patient's fibroblasts the exposure to the extracts (0.1-100 µg/mL) and RA (0.1-100 µM) significantly increased collagen type I and the best results were obtained with 0.1-10 µM RA and 0.1-10 µg/mL of the extracts. LBE showed a greater stimulating effect than RE, likely due to a higher RA content. Moreover, collagen type III expression and matrix metalloproteinase (MMP-1, -2, -9) activity remained unchanged or decreased. The obtained data support the clinical potential of RA-rich extracts and RA itself in modulating the quantitative defect of type I collagen in type I OI.
迷迭香提取物(RE)和香蜂草提取物(LBE)因其具有较高的治疗潜力而特别引起药剂师的关注。I型成骨不全症(OI)是一种由I型胶原蛋白突变引起的遗传性疾病,其特征是胶原蛋白含量减少。本研究的目的是评估这些提取物和迷迭香酸(RA)对OI皮肤成纤维细胞中I型胶原蛋白水平的影响。通过液相色谱-光电二极管阵列检测-质谱联用技术对RE和LBE进行了植物化学分析。通过qPCR、ELISA、SDS-尿素PAGE和蛋白质印迹法分析了I型胶原蛋白在转录水平和蛋白质水平的表达。在OI患者的成纤维细胞中,用这些提取物(0.1-100μg/mL)和RA(0.1-100μM)处理后,I型胶原蛋白显著增加,其中0.1-10μM的RA和0.1-10μg/mL的提取物效果最佳。LBE的刺激作用比RE更大,这可能是由于其RA含量较高。此外,III型胶原蛋白的表达和基质金属蛋白酶(MMP-1、-2、-9)的活性保持不变或降低。所得数据支持富含RA的提取物和RA本身在调节I型OI中I型胶原蛋白定量缺陷方面的临床潜力。